;PMID: 3514847
;source_file_1950.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..44] = [t:0..44]
;1)sentence:[e:50..123] = [t:50..123]
;2)sentence:[e:124..188] = [t:null]
;3)section:[e:null] = [t:129..188]
;4)section:[e:192..260] = [t:192..260]
;5)sentence:[e:264..623] = [t:264..623]
;6)sentence:[e:624..794] = [t:624..794]
;7)sentence:[e:795..1086] = [t:795..1086]
;8)sentence:[e:1087..1420] = [t:1087..1420]
;9)sentence:[e:1421..1570] = [t:1421..1570]
;10)section:[e:1574..1618] = [t:1574..1618]
;Sentence Matching Errors
;ERROR_Entity section missing treebank section[124..188]
;ERROR_Tree section missing entity section[129..188]
;ERROR_Entity not in any tree[139..155] substance "cyclophosphamide"
;ERROR_Entity not in any tree[163..180] substance "aldoketoreductase"
;Token/POS Errors
;ERROR_Token in entity file but not tree[124..127] II.

;section 0 Span:0..44
;J Pharmacol Exp Ther. 1986 Apr;237(1):271-4.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..11] Pharmacol) (NNP:[12..15] Exp)
        (NNP:[16..20] Ther) (.:[20..21] .) (CD:[22..26] 1986)
        (NNP:[27..35] Apr;237-LRB-) (CD:[35..36] 1) (-RRB-:[36..37] -RRB-)
        (CD:[37..41] :271) (::[41..42] -) (CD:[42..44] 4.)))

;sentence 1 Span:50..123
;Interactions between cyclophosphamide and doxorubicin metabolism in rats.
;[71..87]:substance:"cyclophosphamide"
;[92..103]:substance:"doxorubicin"
(SENT
  (NP-HLN
    (NP (NNS:[50..62] Interactions))
    (PP (IN:[63..70] between)
      (NP
        (NP (NN:[71..87] cyclophosphamide)
          (NML-1 (-NONE-:[87..87] *P*)))
        (CC:[88..91] and)
        (NP (NN:[92..103] doxorubicin)
          (NML-1 (NN:[104..114] metabolism)))))
    (PP-LOC (IN:[115..117] in)
      (NP (NNS:[118..122] rats)))
    (.:[122..123] .)))

(ORPH II.)

;section 2 Span:129..188
;Effect of cyclophosphamide on the aldoketoreductase system.
(SEC
  (NP-HLN
    (NP (NN:[129..135] Effect))
    (PP (IN:[136..138] of)
      (NP (NN:[139..155] cyclophosphamide)))
    (PP (IN:[156..158] on)
      (NP (DT:[159..162] the) (NN:[163..180] aldoketoreductase)
          (NN:[181..187] system)))
    (.:[187..188] .)))
;ERROR_Orphan Text from Tree File[123..129] II.

;section 3 Span:192..260
;Dodion P, Akman SR, Tamburini JM, Riggs CE Jr, Colvin OM, Bachur NR.
(SEC
  (FRAG (NNP:[192..198] Dodion) (NNP:[199..200] P) (,:[200..201] ,)
        (NNP:[202..207] Akman) (NNP:[208..210] SR) (,:[210..211] ,)
        (NNP:[212..221] Tamburini) (NNP:[222..224] JM) (,:[224..225] ,)
        (NNP:[226..231] Riggs) (IN:[232..234] CE) (NNP:[235..237] Jr)
        (,:[237..238] ,) (NNP:[239..245] Colvin) (NNP:[246..248] OM)
        (,:[248..249] ,) (NNP:[250..256] Bachur) (NNP:[257..259] NR)
        (.:[259..260] .)))

;sentence 4 Span:264..623
;Under anaerobic conditions, in comparison to liver microsomes obtained from 
;normal controls, liver microsomes obtained from rats pretreated with 
;cyclophosphamide formed significantly less 7-deoxydoxorubicinol aglycone (P
;less  than or equal to .05), whereas the disappearance of doxorubicin and the
; formation of 7-deoxydoxorubicin aglycone were unaffected.
;[411..427]:substance:"cyclophosphamide"
;[454..483]:substance:"7-deoxydoxorubicinol aglycone"
;[545..556]:substance:"doxorubicin"
;[579..606]:substance:"7-deoxydoxorubicin aglycone"
(SENT
  (S
    (PP (IN:[264..269] Under)
      (NP (JJ:[270..279] anaerobic) (NNS:[280..290] conditions)))
    (,:[290..291] ,)
    (PP (IN:[292..294] in)
      (NP
        (NP (NN:[295..305] comparison))
        (PP (TO:[306..308] to)
          (NP
            (NP (NN:[309..314] liver) (NNS:[315..325] microsomes))
            (VP (VBN:[326..334] obtained)
              (NP (-NONE-:[334..334] *))
              (PP (IN:[335..339] from)
                (NP (JJ:[341..347] normal) (NNS:[348..356] controls))))))))
    (,:[356..357] ,)
    (NP-SBJ
      (NP (NN:[358..363] liver) (NNS:[364..374] microsomes))
      (VP (VBN:[375..383] obtained)
        (NP (-NONE-:[383..383] *))
        (PP (IN:[384..388] from)
          (NP
            (NP (NNS:[389..393] rats))
            (VP (VBN:[394..404] pretreated)
              (NP (-NONE-:[404..404] *))
              (PP-MNR (IN:[405..409] with)
                (NP (NN:[411..427] cyclophosphamide))))))))
    (VP (VBD:[428..434] formed)
      (NP
        (ADJP (RB:[435..448] significantly) (JJR:[449..453] less))
         (NN:[454..474] 7-deoxydoxorubicinol) (NN:[475..483] aglycone)
        (PRN (-LRB-:[484..485] -LRB-)
          (S
            (NP-SBJ (NN:[485..486] P))
            (ADJP-PRD
              (ADJP
                (ADJP (JJR:[487..491] less))
                (PP (IN:[493..497] than)
                  (NP-2 (-NONE-:[497..497] *RNR*))))
              (CC:[498..500] or)
              (ADJP (JJ:[501..506] equal)
                (PP (TO:[507..509] to)
                  (NP-2 (-NONE-:[509..509] *RNR*))))
              (NP-2 (CD:[510..513] .05))))
          (-RRB-:[513..514] -RRB-)))
      (,:[514..515] ,)
      (SBAR-ADV (IN:[516..523] whereas)
        (S
          (NP-SBJ-1
            (NP
              (NP (DT:[524..527] the) (NN:[528..541] disappearance))
              (PP (IN:[542..544] of)
                (NP (NN:[545..556] doxorubicin))))
            (CC:[557..560] and)
            (NP
              (NP (DT:[561..564] the) (NN:[566..575] formation))
              (PP (IN:[576..578] of)
                (NP (NN:[579..597] 7-deoxydoxorubicin) (NN:[598..606] aglycone)))))
          (VP (VBD:[607..611] were)
            (VP (JJ:[612..622] unaffected)
              (NP-1 (-NONE-:[622..622] *)))))))
    (.:[622..623] .)))

;sentence 5 Span:624..794
;When directly  investigated, the reduction of 7-deoxydoxorubicin aglycone to 
;7-deoxydoxorubicinol aglycone by microsomes was inhibited by cyclophosphamide
; pretreatment.
;[670..697]:substance:"7-deoxydoxorubicin aglycone"
;[702..731]:substance:"7-deoxydoxorubicinol aglycone"
;[763..779]:substance:"cyclophosphamide"
(SENT
  (S
    (SBAR-ADV
      (WHADVP-2 (WRB:[624..628] When))
      (S
        (NP-SBJ-3 (-NONE-:[628..628] *))
        (ADVP (RB:[629..637] directly))
        (VP (VBN:[639..651] investigated)
          (NP-3 (-NONE-:[651..651] *))
          (ADVP-TMP-2 (-NONE-:[651..651] *T*)))))
    (,:[651..652] ,)
    (NP-SBJ-1
      (NP (DT:[653..656] the) (NN:[657..666] reduction))
      (PP (IN:[667..669] of)
        (NP (NN:[670..688] 7-deoxydoxorubicin) (NN:[689..697] aglycone)))
      (PP (TO:[698..700] to)
        (NP (NN:[702..722] 7-deoxydoxorubicinol) (NN:[723..731] aglycone)))
      (PP (IN:[732..734] by)
        (NP (NNS:[735..745] microsomes))))
    (VP (VBD:[746..749] was)
      (VP (VBN:[750..759] inhibited)
        (NP-1 (-NONE-:[759..759] *))
        (PP (IN:[760..762] by)
          (NP-LGS (NN:[763..779] cyclophosphamide) (NN:[781..793] pretreatment)))))
    (.:[793..794] .)))

;sentence 6 Span:795..1086
;Liver cytosols from controls and cyclophosphamide-treated rats  reduced
;daunorubicin to daunorubicinol and 7-deoxydoxorubicin aglycone to 
;7-deoxydoxorubicinol aglycone at the same rate, which indicates the lack of 
;effect of cyclophosphamide pretreatment on the cytosolic aldoketoreductase.
;[828..844]:substance:"cyclophosphamide"
;[867..879]:substance:"daunorubicin"
;[883..897]:substance:"daunorubicinol"
;[902..929]:substance:"7-deoxydoxorubicin aglycone"
;[934..963]:substance:"7-deoxydoxorubicinol aglycone"
;[1021..1037]:substance:"cyclophosphamide"
;[1068..1085]:substance:"aldoketoreductase"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[795..800] Liver) (NNS:[801..809] cytosols))
      (PP (IN:[810..814] from)
        (NP
          (NP (NNS:[815..823] controls))
          (CC:[824..827] and)
          (NP
            (ADJP (NN:[828..844] cyclophosphamide) (HYPH:[844..845] -)
                  (VBN:[845..852] treated))
            (NNS:[853..857] rats)))))
    (VP
      (VP (VBD:[859..866] reduced)
        (NP=2 (NN:[867..879] daunorubicin))
        (PP=3 (TO:[880..882] to)
          (NP (NN:[883..897] daunorubicinol))))
      (CC:[898..901] and)
      (VP
        (NP=2 (NN:[902..920] 7-deoxydoxorubicin) (NN:[921..929] aglycone))
        (PP=3 (TO:[930..932] to)
          (NP (NN:[934..954] 7-deoxydoxorubicinol) (NN:[955..963] aglycone))))
      (PP (IN:[964..966] at)
        (NP (DT:[967..970] the) (JJ:[971..975] same) (NN:[976..980] rate)))
      (,:[980..981] ,)
      (SBAR-ADV
        (WHNP-1 (WDT:[982..987] which))
        (S
          (NP-SBJ-1 (-NONE-:[987..987] *T*))
          (VP (VBZ:[988..997] indicates)
            (NP
              (NP (DT:[998..1001] the) (NN:[1002..1006] lack))
              (PP (IN:[1007..1009] of)
                (NP
                  (NP (NN:[1011..1017] effect))
                  (PP (IN:[1018..1020] of)
                    (NP (NN:[1021..1037] cyclophosphamide)
                        (NN:[1038..1050] pretreatment)))
                  (PP (IN:[1051..1053] on)
                    (NP (DT:[1054..1057] the) (JJ:[1058..1067] cytosolic)
                        (NN:[1068..1085] aldoketoreductase))))))))))
    (.:[1085..1086] .)))

;sentence 7 Span:1087..1420
;The  results suggest the existence of a microsomal carbonyl reduction system
;for  anthracycline antibiotics and indicate that cyclophosphamide does affect
;the  metabolism of doxorubicin; in rats, this interaction results only in an 
;alteration of the relative concentrations of presumably inactive metabolites,
; the 7-deoxyaglycones.
;[1169..1194]:substance:"anthracycline antibiotics"
;[1213..1229]:substance:"cyclophosphamide"
;[1261..1272]:substance:"doxorubicin"
;[1385..1396]:substance:"metabolites"
;[1403..1419]:substance:"7-deoxyaglycones"
(SENT
  (S
    (S
      (NP-SBJ (DT:[1087..1090] The) (NNS:[1092..1099] results))
      (VP
        (VP (VBP:[1100..1107] suggest)
          (NP
            (NP (DT:[1108..1111] the) (NN:[1112..1121] existence))
            (PP (IN:[1122..1124] of)
              (NP
                (NP (DT:[1125..1126] a) (JJ:[1127..1137] microsomal)
                    (NN:[1138..1146] carbonyl) (NN:[1147..1156] reduction)
                    (NN:[1157..1163] system))
                (PP (IN:[1164..1167] for)
                  (NP (NN:[1169..1182] anthracycline)
                      (NNS:[1183..1194] antibiotics)))))))
        (CC:[1195..1198] and)
        (VP (VBP:[1199..1207] indicate)
          (SBAR (IN:[1208..1212] that)
            (S
              (NP-SBJ (NN:[1213..1229] cyclophosphamide))
              (VP (VBZ:[1230..1234] does)
                (VP (VB:[1235..1241] affect)
                  (NP
                    (NP (DT:[1242..1245] the) (NN:[1247..1257] metabolism))
                    (PP (IN:[1258..1260] of)
                      (NP (NN:[1261..1272] doxorubicin)))))))))))
    (::[1272..1273] ;)
    (S
      (PP-LOC (IN:[1274..1276] in)
        (NP (NNS:[1277..1281] rats)))
      (,:[1281..1282] ,)
      (NP-SBJ (DT:[1283..1287] this) (NN:[1288..1299] interaction))
      (VP (VBZ:[1300..1307] results)
        (ADVP (RB:[1308..1312] only))
        (PP (IN:[1313..1315] in)
          (NP
            (NP (DT:[1316..1318] an) (NN:[1320..1330] alteration))
            (PP (IN:[1331..1333] of)
              (NP
                (NP (DT:[1334..1337] the) (JJ:[1338..1346] relative)
                    (NNS:[1347..1361] concentrations))
                (PP (IN:[1362..1364] of)
                  (NP
                    (NP
                      (ADJP (RB:[1365..1375] presumably)
                            (JJ:[1376..1384] inactive))
                      (NNS:[1385..1396] metabolites))
                    (,:[1396..1397] ,)
                    (NP (DT:[1399..1402] the)
                        (NNS:[1403..1419] 7-deoxyaglycones))))))))))
    (.:[1419..1420] .)))

;sentence 8 Span:1421..1570
;The importance of these findings for the pharmacological  interaction between
;doxorubicin and cyclophosphamide in humans remains to be  investigated.
;[1499..1510]:substance:"doxorubicin"
;[1515..1531]:substance:"cyclophosphamide"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1421..1424] The) (NN:[1425..1435] importance))
      (PP (IN:[1436..1438] of)
        (NP (DT:[1439..1444] these) (NNS:[1445..1453] findings)))
      (PP (IN:[1454..1457] for)
        (NP
          (NP (DT:[1458..1461] the) (JJ:[1462..1477] pharmacological)
              (NN:[1479..1490] interaction))
          (PP (IN:[1491..1498] between)
            (NP (NN:[1499..1510] doxorubicin) (CC:[1511..1514] and)
                (NN:[1515..1531] cyclophosphamide)))
          (PP-LOC (IN:[1532..1534] in)
            (NP (NNS:[1535..1541] humans))))))
    (VP (VBZ:[1542..1549] remains)
      (S-PRD
        (NP-SBJ-1 (-NONE-:[1549..1549] *))
        (VP (TO:[1550..1552] to)
          (VP (VB:[1553..1555] be)
            (VP (VBN:[1557..1569] investigated)
              (NP-1 (-NONE-:[1569..1569] *)))))))
    (.:[1569..1570] .)))

;section 9 Span:1574..1618
;PMID: 3514847 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1574..1578] PMID) (::[1578..1579] :) (CD:[1580..1587] 3514847)
        (NN:[1588..1589] -LSB-) (NNP:[1589..1595] PubMed) (::[1596..1597] -)
        (NN:[1598..1605] indexed) (IN:[1606..1609] for)
        (NNP:[1610..1618] MEDLINE-RSB-)))
